2014
DOI: 10.3233/jad-141074
|View full text |Cite
|
Sign up to set email alerts
|

Lower Brain 18F-Fluorodeoxyglucose Uptake But Normal 11C-Acetoacetate Metabolism in Mild Alzheimer's Disease Dementia

Abstract: Regional brain energy substrate hypometabolism in mild AD dementia may be specific to impaired glucose uptake and/or utilization. This suggests a potential avenue for compensating brain energy deficit in AD dementia with ketones.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
131
0
4

Year Published

2017
2017
2022
2022

Publication Types

Select...
7
2

Relationship

2
7

Authors

Journals

citations
Cited by 155 publications
(142 citation statements)
references
References 33 publications
7
131
0
4
Order By: Relevance
“…Our studies also show that brain ketone uptake is entirely normal in exactly the same Alzheimer or MCI cases that have lower brain glucose uptake (Castellano et al, 2015Croteau et al, 2017). So, the good news is that the brain's energy problem in Alzheimer's disease is specific to glucose and does not affect brain ketone uptake.…”
Section: Keto-neurotherapeuticssupporting
confidence: 58%
See 1 more Smart Citation
“…Our studies also show that brain ketone uptake is entirely normal in exactly the same Alzheimer or MCI cases that have lower brain glucose uptake (Castellano et al, 2015Croteau et al, 2017). So, the good news is that the brain's energy problem in Alzheimer's disease is specific to glucose and does not affect brain ketone uptake.…”
Section: Keto-neurotherapeuticssupporting
confidence: 58%
“…Much later, we quantified the brain glucose deficit (mmol/100 g/min) in cognitively healthy older people, MCI and Alzheimer's disease compared to healthy young adults. Without having done so, we could not have estimated the therapeutic target for ketones to bypass the energy deficit (Nugent et al, 2014;Castellano et al, 2015;Cunnane et al, 2016a, b;Croteau et al, 2017). It is laborious and it is more expensive but, in the development of keto-neurotherapeutics, quantification was essential at several levels.…”
Section: Perspectivementioning
confidence: 99%
“…Brain glucose uptake is 10-15% lower during normal aging (Nugent et al 2014), and can be up to 35% 16 lower in certain brain regions in neurodegenerative diseases such as Alzheimer's disease (AD) 17 (Castellano et al 2015). Several studies suggest that brain glucose hypometabolism potentially 18 contributes to the onset and/or progression of AD (Cunnane et al 2016;Mosconi et al 2005;Nugent et al 19 2014;Reiman et al 2004;Schöll et al 2011).…”
mentioning
confidence: 99%
“…Neuronal hypometabolism appears to be foundation in pathogenesis of many ND (Castellano et al, 2015): consequences of metabolic disorders set off in the preclinical stages of the disease. This is a common ground for new therapies for ND, especially in those where neuroprotection is the key (Stafstrom et al, 2012).…”
Section: Resultsmentioning
confidence: 99%